Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person13
Zymeworks Inc.
Company
Freshworks Inc.
Company
PIXELWORKS, INC
Company
A10 Networks, Inc.
Company
Lunai Bioworks Inc.
Company
Bath & Body Works, Inc.
Company
AVIAT NETWORKS, INC.
Company
UPWORK, INC
Company
Summit Networks Inc.
Company
Arista Networks, Inc.
Company
MDWerks, Inc.
Company
WORKIVA INC
Company
Workday, Inc.
Company
Primary record11
Faeth Therapeutics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of F
Zymeworks Inc. filed DEF 14A
SEC form DEF 14A filed by Zymeworks Inc. (CIK 1937653) on 2026-10-26.
Zymeworks Inc. filed 8-K
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT On October 22, 2026, Zymeworks Inc. and its subsidiary Zymeworks BC Inc. (together, the “Company”) entered into a Collaboration and License Agreement (the “Collaborati
Quince Therapeutics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, each of June Bray, David Lamond and Chr
Theravance Biopharma, Inc. filed SCHEDULE 13D/A
0001193125-26-402801.txt : 20260925 SCHEDULE 13D/A 1 primary_doc.xml X0202 SCHEDULE 13D/A 0001357550 XXXXXXXX LIVE 4 Ordinary Share $0.00001 Par Value 09/23/2026 false 0001583107 G8807B106 Theravance Biopharma, Inc. Ugla
Zymeworks Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Contingent Value Rights Agreement On September 22, 2026, in connection with the consummation of the Merger and in accordance with the Merger Agreement, Zymeworks, Com
Theravance Biopharma, Inc. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. Theravance Biopharma, Inc. ( Theravance Biopharma or the Company ) held an extraordinary general meeting on September 18, 2026 (the Extraordinary General Me
Gossamer Bio, Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 16, 2026, upon the recommendation of the Nominatin
Theravance Biopharma, Inc. filed 8-K
Item 8.01. Other Events. As previously disclosed, on June 28, 2026, Theravance Biopharma, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (“ Theravance Biopharma ” or th
Theravance Biopharma, Inc. filed 8-K
Item 8.01. Other Events. On August 25, 2026, Theravance Biopharma, Inc. (the “Company”) made available a presentation regarding the Phase 3 CYPRESS Study (0197) of ampreloxetine in patients with symptomatic neurogenic or
Zymeworks Inc. filed 8-K
ITEM 7.01 REGULATION FD DISCLOSURES On August 25, 2026, Zymeworks Inc. (“Company”) issued a press release announcing that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (“FDA”) approval